Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib

Journal of Clinical Oncology

Volumn 31, Issue 7, 2013, Pages

  Jacobs, Corbin ^a   Kim, Dong Wook Nathan ^a   Straka, Christopher ^a   Timmerman, Robert D ^a   Brugarolas, James ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; EVEROLIMUS; PAZOPANIB;

AGED; ARTICLE; BRAIN METASTASIS; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASE REPORT; CEREBELLUM; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; COUGHING; DISEASE ASSOCIATION; DRUG MEGADOSE; FRONTAL LOBE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; KIDNEY CARCINOMA; MALE; MEDIASTINAL ADENOPATHY; MEDIASTINUM LYMPH NODE; NEPHRECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SURVIVAL TIME; TREATMENT DURATION;

AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FATAL OUTCOME; HUMANS; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; NEPHRECTOMY; PYRIMIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84875742854     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.0501     Document Type: Article

References (27)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62:10-29, 2012.
2. Cohen HT, McGovern FJ: Renal-cell carcinoma. N Engl J Med 353:2477- 2490, 2005. (Pubitemid 41770167)
3. Yang XJ, Tan MH, Kim HL, et al: A molecular classification of papillary renal cell carcinoma. Cancer Res 65:5628-5637, 2005. (Pubitemid 40911163)
4. Pignot G, Elie C, Conquy S, et al: Survival analysis of 130 patients with papillary renal cell carcinoma: Prognostic utility of type 1 and type 2 subclassification. Urology 69:230-235, 2007. (Pubitemid 46274917)
5. Waldert M, Haitel A, Marberger M, et al: Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC. BJU Int 102:1381-1384, 2008.
6. Klatte T, Pantuck AJ, Said JW, et al: Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res 15:1162-1169, 2009.
7. Schouten LJ, Rutten J, Huveneers HA, et al: Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94:2698-2705, 2002. (Pubitemid 34478086)
8. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al: Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22:2865-2872, 2004. (Pubitemid 41079905)
9. Sperduto PW, Chao ST, Sneed PK, et al: Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: A multi-institutional analysis of 4, 259 patients. Int J Radiat Oncol Biol Phys 77:655-661, 2010.
10. Brugarolas J: Research translation and personalized medicine, in Figlin RA, Rathmell WK, Rini BI (eds): Renal Cell Carcinoma. New York, NY, Springer, 2012, pp 161-191.
11. Walid MS, Johnston KW: Successful treatment of a brain-metastasized renal cell carcinoma. Ger Med Sci 7: Doc28, 2009.
12. Mai KT, Landry DC, Robertson SJ, et al: A comparative study of metastatic renal cell carcinoma with correlation to subtype and primary tumor. Pathol Res Pract 197:671-675, 2001. (Pubitemid 33014800)
13. Decker DA, Decker VL, Herskovic A, et al: Brain metastases in patients with renal cell carcinoma: Prognosis and treatment. J Clin Oncol 2:169-173, 1984. (Pubitemid 14138404)
14. Maor MH, Frias AE, Oswald MJ: Palliative radiotherapy for brain metastases in renal carcinoma. Cancer 62:1912-1917, 1988. (Pubitemid 18261814)
15. Nussbaum ES, Djalilian HR, Cho KH, et al: Brain metastases: Histology, multiplicity, surgery, and survival. Cancer 78:1781-1788, 1996.
16. Wrónski M, Maor MH, Davis BJ, et al: External radiation of brain metastases from renal carcinoma: A retrospective study of 119 patients from the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys 37:753-759, 1997. (Pubitemid 27181304)
17. Mori Y, Kondziolka D, Flickinger JC, et al: Stereotactic radiosurgery for brain metastasis from renal cell carcinoma. Cancer 83:344-353, 1998. (Pubitemid 28317815)
18. Sheehan JP, Sun MH, Kondziolka D, et al: Radiosurgery in patients with renal cell carcinoma metastasis to the brain: Long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg 98:342-349, 2003. (Pubitemid 36151030)
19. Ward JE, Stadler WM: Pazopanib in renal cell carcinoma. Clin Cancer Res 16:5923-5927, 2010.
20. Rini BI, Escudier B, Tomczak P, et al: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet 378:1931-1939, 2009.
21. Lim ZD, Mahajan A, Weinberg J, et al: Outcome of patients with renal cell carcinoma metastatic to the brain treated with sunitinib without local therapy. Am J Clin Oncol [epub ahead of print on March 20, 2012].
22. Kelly PJ, Weiss SE, Sher DJ, et al: Sunitinib-induced pseudoprogression after whole-brain radiotherapy for metastatic renal cell carcinoma. J Clin Oncol 28:e433-e435, 2010.
23. Medioni J, Cojocarasu O, Belcaceres JL, et al: Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann Oncol 18:1282-1283, 2007. (Pubitemid 47244377)
24. Négrier S: Case report 3: Sunitinib malate in patients with cerebellar metastases. Eur J Cancer 5:S32-S34, 2007 (suppl).
25. Patyna S, Peng G: Distribution of sunitinib and its active metabolite in brain and spinal cord tissue following oral or intravenous administration in rodents and monkeys. Eur J Cancer 4:21, 2006 (suppl; abstr 56).
26. Minocha M, Khurana V, Mitra AK: Determination of pazopanib (GW- 786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC/MS-MS). J Chromatogr B Analyt Technol Biomed Life Sci 901:85-92, 2012.
27. Iwamoto FM, Lamborn KR, Robins HI, et al: Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro-Oncology 12:855-861, 2010.